anti-PSMA monoclonal antibody MDX1201-A488 for Prostate Cancer

"This clinical trial is open to patients aged 36-74. For the population younger than 18, there are 73 studies and for those over 65, 1254 studies can be found."

"As this is early stage research, the hazard rating for this pharmacological study was assessed as a 1 due to limited evidence of safety and efficacy."

"This trial is enrolling 20 patients with stage iv prostate cancer that are between 36 and 74 years of age. In order to qualify, the following conditions must be met: ECOG performance status; men agreeing to contraceptive use for 6 months after the duration of study participation; confirmed adenocarcinoma diagnosis without small cell, neuroendocrine or transitional cases; life expectancy above 10 years determined by physician; PSA level >10 ng/ml ; Gleason score >=7 ; Clinical stage>=T2c; bone scan not showing skeletal metastases (x-ray film or MRI tests may be done if results unclear); 3"

"With reference to the clinicaltrials.gov website, it appears that this experiment is not currently recruiting participants. This trial was originally posted on March 5th 2015 and last refreshed on March 17th 2022. Nevertheless, there are 1259 other studies actively seeking volunteers at present."